Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-120P is a pseudogene comprised of nucleic acid sequence similar to U6 small nuclear RNA (snRNA), a key RNA involved in the spliceosomal machinery that catalyzes pre-mRNA splicing[1][3]. Unlike the functional U6 snRNA gene, RNU6-120P does not encode a functional RNA molecule and is generally considered a product of retrotransposition events mediated by LINE-1 (L1) and other elements[3]. Such pseudogenes are widespread in mammalian genomes and typically lack introns and may contain scattered base mismatches compared to their parental gene[3]. They serve as markers of retrotransposition dynamics and genome evolution, but do not have known biological activity, receptor function, or disease relevance. In summary, RNU6-120P is a non-functional, processed pseudogene derived from the U6 snRNA gene, with no known role as a therapeutic target, no known biological function, and no relevance in current drug development or marker applications[3]. Its primary interest is in genomics and evolutionary biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 120, pseudogene (RNU6-120P).